Cipher Pharmaceuticals

Cipher Pharmaceuticals CPHRF Stock

$9.30   -3.326400%
Add to favorites
Market Cap
$236.36M
LOW - HIGH [24H]
$9.32 - $9.39
VOLUME [24H]
$1.05K
P/E Ratio
7.04
Earnings per share
$1.32
ISIN
CA17253X1050
Price   Prediction

Cipher Pharmaceuticals Price Chart

Sorry, that's all we've gotfor now...

Cipher Pharmaceuticals (CPHRF) stock price today is 9.3 USD on OTC Markets OTCQX (-3.33% on the day). Updated .

Cipher Pharmaceuticals CPHRF Financial and Trading Overview

Cipher Pharmaceuticals stock price 9.3 USD
Previous Close 9.94 USD
Open 10.28 USD
Bid 9.41 USD x 170000
Ask 9.45 USD x 30000
Day's Range 9.62 - 10.28 USD
52 Week Range 9.27 - 15 USD
Volume 300 USD
Avg. Volume 3.74K USD
Market Cap 244.49M USD
Beta (5Y Monthly) N/A
PE Ratio (TTM) 7.2878785
EPS (TTM) 1.32 USD
Forward Dividend & Yield N/A (0%)
Ex-Dividend Date N/A
1y Target Est N/A

CPHRF Valuation Measures

Enterprise Value 229.08M USD
Trailing P/E 7.2878785
Forward P/E 19.24
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) 4.9402504
Price/Book (mrq) 1.6660893
Enterprise Value/Revenue 4.629
Enterprise Value/EBITDA 7.345

Trading Information

Cipher Pharmaceuticals Stock Price History

Beta (5Y Monthly) N/A
52-Week Change 4.30%
S&P500 52-Week Change 13.32%
52 Week High 15 USD
52 Week Low 9.27 USD
50-Day Moving Average 9.8 USD
200-Day Moving Average 11.35 USD

CPHRF Share Statistics

Avg. Volume (3 month) 3.74K USD
Avg. Daily Volume (10-Days) 3.25K USD
Shares Outstanding 25.42M
Float 14.78M
Short Ratio 0.97
% Held by Insiders 42.73%
% Held by Institutions 1.32%
Shares Short 11.43K
Short % of Float N/A
Short % of Shares Outstanding 0.040%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2025
Most Recent Quarter (mrq) September 30, 2026
Next Fiscal Year End December 31, 2026

Profitability

Profit Margin 69.47%
Operating Margin (ttm) 49.06%
Gross Margin 81.36%
EBITDA Margin 63.02%

Management Effectiveness

Return on Assets (ttm) 9.61%
Return on Equity (ttm) 26.42%

Income Statement

Revenue (ttm) 49.49M USD
Revenue Per Share (ttm) 1.95 USD
Quarterly Revenue Growth (yoy) -1.00000000000000000000000000000000%
Gross Profit (ttm) 40.27M USD
EBITDA 31.19M USD
Net Income Avi to Common (ttm) 34.38M USD
Diluted EPS (ttm) 1.32
Quarterly Earnings Growth (yoy) 98.09%

Balance Sheet

Total Cash (mrq) 15.33M USD
Total Cash Per Share (mrq) 0.61 USD
Total Debt (mrq) 644K USD
Total Debt/Equity (mrq) 0.44 USD
Current Ratio (mrq) 1.991
Book Value Per Share (mrq) 5.774

Cash Flow Statement

Operating Cash Flow (ttm) 24.76M USD
Levered Free Cash Flow (ttm) 14.99M USD

Profile of Cipher Pharmaceuticals

Country United States
State ON
City Mississauga
Address 5750 Explorer Drive
ZIP L4W 0A9
Phone 905 602 5840
Website https://www.cipherpharma.com
Industry Drug Manufacturers - Specialty & Generic
Sector(s) Healthcare
Full Time Employees N/A

Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibrillation to sinus rhythm in adults; Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with acute coronary syndrome; and Natroba for the topical treatment of head lice and scabies infestations in adult and pediatric patients. The company's licensed products comprise Absorica, an oral retinoid for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Conzip, an opioid agonist for the management of moderate to moderately severe chronic pain in adults; and Lipofen, an adjunctive therapy to diet to reduce elevated LDL-C, total-C, triglycerides, and Apo B, as well as to increase HDL-C. Its pipeline products include piclidenoson CF-101, a novel chemical entity for moderate to severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical formulation of terbinafine, which is in phase 3 clinical trial for treatment of onychomycosis; and DTR-001, a tattoo removal cream. The company was founded in 2000 and is headquartered in Mississauga, Canada.

Q&A For Cipher Pharmaceuticals Stock

What is a current CPHRF stock price?

Cipher Pharmaceuticals CPHRF stock price today per share is 9.3 USD.

How to purchase Cipher Pharmaceuticals stock?

You can buy CPHRF shares on the OTC Markets OTCQX exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Cipher Pharmaceuticals?

The stock symbol or ticker of Cipher Pharmaceuticals is CPHRF.

Which industry does the Cipher Pharmaceuticals company belong to?

The Cipher Pharmaceuticals industry is Drug Manufacturers - Specialty & Generic.

How many shares does Cipher Pharmaceuticals have in circulation?

The max supply of Cipher Pharmaceuticals shares is 25.42M.

What is Cipher Pharmaceuticals Price to Earnings Ratio (PE Ratio)?

Cipher Pharmaceuticals PE Ratio is 7.04545450 now.

What was Cipher Pharmaceuticals earnings per share over the trailing 12 months (TTM)?

Cipher Pharmaceuticals EPS is 1.32 USD over the trailing 12 months.

Which sector does the Cipher Pharmaceuticals company belong to?

The Cipher Pharmaceuticals sector is Healthcare.

$2.18T
Total marketcap
$71.79B
Total volume
BTC 58.99%   •   ETH 10.06%
Dominance
Select currency